The UK is witnessing a growing surge in interest surrounding copyright substances. Beyond the well-established use of psilocybin and LSD, investigators and explorers are increasingly delving into less-charted frontiers, particularly the copyright compound and the nascent cannabinoid, CBG compound. This expanding movement encompasses clinical trials